March 16, 2010ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction
Key result
Treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates in patients with HFPEF, where 60% of all deaths were cardiovascular.
Why the study?
Does irbesartan alter overall mortality or the distribution of mode of death in patients with heart failure and a preserved ejection fraction?
Population
Patients with heart failure and a preserved ejection fraction (HFPEF) enrolled in the I-Preserve trial
Comparison
Irbesartan vs Placebo
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Irbesartan offers no mortality benefit in HFpEF; confirms neutral effect of ARBs on overall and mode-specific death.
Key Points
- This research aims to evaluate the mode of death in patients with heart failure and preserved ejection fraction (HFPEF) and the effect of irbesartan on mortality rates.
- Analyzed death modes of patients from the I-Preserve trial, involving consensus review by a clinical end-point committee.
- Annual mortality rate observed was 5.2% with no significant differences between placebo and irbesartan groups.
- Categorized deaths as cardiovascular (60%), noncardiovascular (30%), and unknown (10%).
- Cardiovascular causes accounted for 60% of deaths, with sudden death (26%) and heart failure (14%) as the most common.
- Treatment with irbesartan did not alter the overall mortality rate or specific modes of death.
- No significant differences were found in the distribution of mode-specific mortality rates between placebo and irbesartan groups.
Study Design
Type
RCT
Structured PICO
Does irbesartan alter overall mortality or the distribution of mode of death in patients with heart failure and a preserved ejection fraction?
P
Population
Patients with heart failure and a preserved ejection fraction (HFPEF) enrolled in the I-Preserve trial
I
Intervention
Irbesartan
C
Comparator
Placebo
O
Outcome
Mode of death (overall mortality and distribution of mode-specific mortality rates)hard clinical
In patients with HFpEF, the majority of deaths are cardiovascular (predominantly sudden death and heart failure), and treatment with irbesartan does not alter overall or mode-specific mortality.
Cite This Study
Zile et al. (2010) conducted an RCT in Heart failure with preserved ejection fraction (HFPEF). Irbesartan vs. Placebo was evaluated on Mode of death and mortality rate. Treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates in patients with HFPEF, where 60% of all deaths were cardiovascular.